Corporate Profile


Enabling the future of cell-based research... by creating Inspired Cell Solutions where we deliver excellence with speed


H


orizon Discovery Group plc is a world-leading gene editing com- pany that designs and engineers


genetically-modified cells and then applies them in research and clinical applications that advance human health. The core capabilities of Horizon are built


around its proprietary translational genomics platform, a highly precise and flex- ible suite of gene editing tools (rAAV, ZFN and CRISPR) able to alter almost any gene sequence in human or mammalian cell-lines. Horizon offers more than 23,000 cata-


logue products and related research ser- vices, almost all of which are based on the generation and application of cell and ani- mal models that accurately recapitulate the disease-causing genetic anomalies found in diseases such as cancer.


Powering up discovery pipelines with screening solutions Horizon is the go-to cell engineering expert where cell lines are used directly, or deployed with adjacent technologies, to create an unrivalled toolbox designed to enable customers to perform their own experiments or to partner with Horizon for delivery of contract services. Horizon’s leading Functional Genomic


Screen Services, utilising CRISPR and siRNA technologies, assist with finding and


sis producing results in a reduced time. Commanding outstanding genetic control for any gene modulation or editing workflow.


validating novel drug targets and exploring gene function. The best-in-class CRISPR KO (knockout), CRISPRi (interference) and CRISPRa (activation) screening platforms can significantly advance its customers’ drug development programmes by offering the highest quality and greatest confidence in its screening results. With screening libraries in its portfolio,


Horizon’s offering can accelerate clients’ research with functional genomics screening libraries. Drug targets can be found faster via gene family, biological pathway or whole genome library screens. Clients can choose from RNAi, CRISPR-Cas9, CRISPR activa- tion crRNA libraries or cDNA and ORF libraries. Custom screening libraries are available as ready-made or in a more flexi- ble format employing cherry-picked capabil- ities, choosing from predesigned product lines allowing the gene selection of interest. Horizon provides best-in-class services


profiling drugs performance, helping clients identify patient cohort faster and select the most relevant drug screening forecast, avail- able as single and combination drug screen- ing formats. Adopting a partnership approach to all of its projects, giving superior support to every client.


Mastering genes of interest Gene editing reagents within Horizon’s gene modulation portfolio allow for reliable and efficient gain-or loss-of- function gene knockout and custom oligo synthe-


24


Liberating biomanufacturing Horizon gives access to the best biomanufac- tured GS null CHO cell lines which are opti- mised for suspension culture bioproduction. Agreements are available via highly flexible, royalty-free licence structures. Unlocking the power of CHO cells lines, liberating clients from excessive licensing restrictions. Within Horizon’s custom cell line devel-


opment programme, engineering of the opti- mum host can be achieved at the highest level. Client’s CHO expression platforms can be optimised to suit their specific needs. Horizon’s vast experience working with rAAV and CRISPR genome editing tech- nologies can be leveraged and taken advan- tage of in creating adaptable solutions by allowing clients’ cell lines to be used in the process or by selecting Horizon’s own.


Redefining assay development, validation and routine monitoring Horizon’s Reference Standards are available in a variety of product types and formats to suit clients’ specific assays and workflows. Horizon offers the world’s largest oncology reference standard panel, OncoSpan as well as multi- and single-gene standards for liq- uid biopsy and NGS assays.


Supporting and enhancing the scientific community Horizon’s commercial offering has been adopted by circa 1,600 unique research organisations in more than 50 countries as well as in the company’s own R&D pipeline to support a greater understanding of the genetic drivers of disease and the development of molecular, cell and gene therapies that can be prescribed on a personalised basis. https://www.horizondiscovery.com/research- services/functional-genomic-screening/crispr- screening.


Drug Discovery World Winter 2018/19


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68